Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Clinical trial NCT06401980 · RECRUITING

Trial details

NCT number: NCT06401980
Sponsor: Swiss Cancer Institute
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Castration-resistant Prostate Cancer

Start date: 2024-10-22
Primary completion: 2030-06-01
Enrollment: 162

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.